All In Biotech

Drug Trial Radar · NCT07725939

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (SCALA)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

402

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Jun 29, 2029

Study completion Jun 29, 2029

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jul 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

Conditions

  • Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Interventions

  • GalvokimigBiological

    Drug: Galvokimig Pharmaceutical form: Solution for injection

  • PlaceboBiological

    Drug: Placebo Pharmaceutical form: Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD)Time frame: Up to Week 60

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Copd01 50021

    Encino, California · Recruiting

  • Copd01 50016

    Westminster, California · Recruiting

  • Copd01 50011

    Miami, Florida · Recruiting

  • Copd01 50008

    Rincon, Georgia · Recruiting

  • Copd01 50017

    Charlotte, North Carolina · Recruiting

  • Copd01 50003

    Columbus, Ohio · Recruiting

  • Copd01 50019

    Medford, Oregon · Recruiting

  • Copd01 50002

    DuBois, Pennsylvania · Recruiting

  • Copd01 50020

    North Charleston, South Carolina · Recruiting

  • Copd01 50004

    Rock Hill, South Carolina · Recruiting

  • Copd01 50009

    Spartanburg, South Carolina · Recruiting

  • Copd01 50010

    Union, South Carolina · Recruiting

  • Copd01 50001

    Boerne, Texas · Recruiting

  • Copd01 50006

    McKinney, Texas · Recruiting

  • Copd01 50005

    Tomball, Texas · Recruiting

  • Copd01 50013

    Seattle, Washington · Recruiting

  • Copd01 20001

    Beijing, China · Recruiting

  • Copd01 20004

    Chengdu, China · Recruiting

  • Copd01 20006

    Guangzhou, China · Recruiting

  • Copd01 20003

    Hangzhou, China · Recruiting

  • Copd01 20005

    Hangzhou, China · Recruiting

  • Copd01 20002

    Nanchang, China · Recruiting

  • Copd01 20008

    Shenzhen, China · Recruiting

  • Copd01 20012

    Shijiazhuang, China · Recruiting

  • Copd01 20015

    Yangzhou SHI, China · Recruiting

  • Copd01 20007

    Zhanjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.